Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 43 results for Disease + Therapy RSS
The Battlefield Medicine program supports military readiness in far-forward deployed settings by overcoming logistical obstacles to manufacturing and delivery of urgently needed pharmaceutical products used to treat emerging threats.
The Dialysis-Like Therapeutics (DLT) program aims to support force protection and military readiness by improving critical care in low-resource environments and delivering a new tool for rapid response to emerging infectious disease threats. DLT specifically addresses a life-threatening blood infection known as sepsis, but DARPA is working to expand the DLT technology to also mitigate threats from harmful bacteria, viruses, fungi, and toxic agents in the blood.
Microbial infections are a problem of particular concern to the Department of Defense (DoD). The DoD has long recognized the warfighter’s outsized risk of exposure to infectious disease, including the rise of antimicrobial resistant (AMR) and multidrug resistant (MDR) pathogens that have challenged military wound care in Iraq and Afghanistan. Furthermore, the responsibility of the DoD to protect the homeland encompasses biological threat agents, including bacterial threats, for which effective countermeasures are critical.
The In Vivo Nanoplatforms (IVN) program supports military readiness through the development of in vivo sensing technologies and therapeutics that facilitate optimal health and performance in individual warfighters. The program pursues technologies that provide early indication of physiological abnormalities or illness that can be proactively addressed with therapeutics or supportive care.
Viral pathogens pose a continuous and shifting biological threat to military readiness and national security overall in the form of infectious disease with pandemic potential. Today’s limited vaccines and other antivirals are often circumvented by quickly mutating viruses that evolve to develop resistance to treatments that are carefully formulated to act only specific strains of a virus.